Drug Trial Radar · NCT05718817
An Open-label Study of XEN1101 in Epilepsy
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
880
Planned (sponsor's estimate)
Start
Apr 25, 2023
Primary completion
Apr 2033
Study completion Jun 2033
Sponsor
- Lead sponsor
- Xenon Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years.
Conditions
- Focal Epilepsy
- Tonic-Clonic Seizures
Interventions
XEN1101Drug
XEN1101 capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- The adverse eventsTime frame: From the start of treatment in the open-label extension (OLE) study through 8 weeks after the last dose.
Locations
153 sites in 25 countries. Site status is shown where the registry gives one.
Xenoscience
Phoenix, Arizona
University of Arizona - Health Sciences
Tucson, Arizona
Clinical Trials, Inc
Little Rock, Arkansas
Brain Science Research Institute
Los Angeles, California
UC Irvine Health
Orange, California
University of California, Davis Clinical & Translational Science Center Clinical Research (CCRC)
Sacramento, California
University of Colorado Hospital Anschutz Outpatient Pavilion
Aurora, Colorado
Mayo Clinic Florida
Jacksonville, Florida
Serenity Research Center, LLC
Miami, Florida
Research Institute of Orlando, LLC
Orlando, Florida
Panhandle Research & Medical Clinic
Pensacola, Florida
University of South Florida
Tampa, Florida
Encore Medical Research of Weston, LLC
Weston, Florida
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Consultants in Epilepsy and Neurology
Boise, Idaho
Indiana University School of Medicine
Indianapolis, Indiana
The University of Kansas Medical Center
Kansas City, Kansas
Bluegrass Epilepsy Research, LLC
Lexington, Kentucky
Kentucky Clinic
Lexington, Kentucky
MMP Neurology
Scarborough, Maine
University of Maryland Medical Center
Baltimore, Maryland
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
UMass Chan Medical School
Worcester, Massachusetts
University of Michigan Hospitals
Ann Arbor, Michigan
Wayne State University
Detroit, Michigan
Michigan State University
East Lansing, Michigan
Cornwell Health (Spectrum Health Hospitals)
Grand Rapids, Michigan
Minneapolis Clinic of Neurology
Burnsville, Minnesota
Saint Louis University Medical School
St Louis, Missouri
Northeast Epilepsy Group
Hackensack, New Jersey
Dent Neurosciences Research Center
Buffalo, New York
New York University Comprehensive Epilepsy Center
New York, New York
Mount Sinai Health
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Montefiiore Medical Center
The Bronx, New York
Onsite Clinical Solutions
Charlotte, North Carolina
Duke University
Durham, North Carolina
Meridian Clinical Research, LLC
Raleigh, North Carolina
Summa Health
Akron, Ohio
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.